Virus therapy for pancreatic cancer
Part of Cancer clinical trials.
This trial tests a modified virus injected directly into pancreatic tumors using an endoscopy. It is designed to target and attack cancer cells while sparing healthy tissue, and may be an option for people whose cancer is still confined to the pancreas and nearby lymph nodes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have pancreatic adenocarcinoma that has not spread beyond the pancreas and nearby lymph nodes.
- You have had no more than one prior treatment (like chemotherapy before surgery), and at least 4 weeks have passed since your last dose.
- You can have an endoscopy with ultrasound, and your tumor can be reached safely with a needle.
- You are 18 years or older.
- You are not pregnant, breastfeeding, and agree to use two forms of birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment that combines a cancer-killing virus with an immunotherapy drug (a PD-1 inhibitor) for advanced pancreatic cancer. It aims to see if this combination can help shrink tumors and improve outcomes for patients who have already tried chemotherapy.
This trial tests giving a combination of an oncolytic virus, immunotherapy (PD-1 inhibitor), and chemotherapy before surgery to shrink pancreatic tumors and make them easier to remove. The goal is to improve outcomes for people with borderline resectable or locally advanced pancreatic cancer.
This trial tests a new type of vaccine (called ONVAX-01) combined with an immunotherapy drug and chemotherapy for advanced pancreatic cancer. The goal is to see if this combination can help your immune system fight the cancer more effectively than the usual treatments alone.
This study tests a more frequent schedule of the experimental drug VCN-01 along with standard chemotherapy (nab-paclitaxel and gemcitabine) for people newly diagnosed with pancreatic cancer that has spread. The goal is to see if the virus-based therapy can help shrink tumors better.
This trial tests a new treatment called VRT106 combined with chemotherapy for people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a cancer vaccine (ELI-002 7P) for people with pancreatic cancer that hasn't spread to other parts of the body. It may be given alone or with another drug (tislelizumab) that helps the immune system fight cancer. The goal is to see if these treatments can help keep the cancer from coming back after surgery or chemotherapy.
Hear when a new Adenocarcinoma of Pancreas trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.